Cystic Fibrosis (CF) Market Insights, Epidemiology and Market Forecast-2027

DelveInsight Business Research LLP


Albany, NY -- (SBWIRE) -- 10/03/2018 -- DelveInsight has announced the addition of the "Cystic Fibrosis (CF) Market Insights, Epidemiology and Market Forecast-2027" to their offering.

DelveInsight's "Cystic Fibrosis (CF) -Market Insights, Epidemiology & Market Forecast-2027" Report provides an overview of the disease and market size of Cystic Fibrosis for the seven major markets i.e., United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the overview, treatment practice and forecasted epidemiology of Cystic Fibrosis from 2018 to 2027 segmented by seven major markets.

Cystic Fibrosis is a progressive, genetic disease that causes persistent lung infections and limits the ability to breathe over time. In people with CF, a defective gene causes a thick, sticky build-up of mucus in the lungs, pancreas, and other organs. In the lungs, the mucus clogs the airways and traps bacteria leading to infections, extensive lung damage, and eventually, respiratory failure. In the pancreas, the mucus prevents the release of digestive enzymes that allow the body to break down food and absorb vital nutrients.
More than 30,000 people are living with cystic fibrosis in the US. Approximately 1,000 new cases of CF are diagnosed each year and more than 75 percent of people with CF are diagnosed by age 2. More than half of the CF population is age 18 or older. The incidence of CF in Germany is between 1 in 3300 and 1 in 4800. Italy has the highest incidence of 1 in 2438 births among the EU5 countries. Women continue to remain a significant risk factor for death (hazard ratio of 2.22%) despite accounting for variables known to influence CF mortality. Women were also found to become colonized earlier with several bacteria and to have worse outcomes with common CF pathogens as compared to men.

Geography Covered

1. United States
2. EU5 (Germany, France, Italy, Spain and the United Kingdom)
3. Japan

Study Period: 2018-2027

Cystic Fibrosis Drug Companies

1. Vertex Pharmaceuticals
2. Genentech
3. Merck

And many others

Drugs covered

1. Ivacaftor
2. Symdeko

And many others

Report Scope

The report covers the descriptive overview of Cystic Fibrosis explaining its pathophysiology, disease classification, diagnostic approaches and treatment algorithm. The report provides the insight into the epidemiology of the disease and its treatment in the 7 MM covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan. The report is a comprehensive account of both the current and emerging therapies covering the impact of the new therapies on the current treatment landscape. The report also reviews the detailed historical and forecasted Cystic Fibrosis market size covering the drug outreach in 7MM. The report provides the understanding of the future competition in Cystic Fibrosis by reviewing the market drivers and barriers.